Trials / Completed
CompletedNCT00797511
Immunogenicity and Safety of Adacel Polio Vaccine
Immunogenicity and Safety of ADACEL POLIO (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose in Healthy Children in Taiwan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 6 Years – 8 Years
- Healthy volunteers
- Accepted
Summary
The present study is designed to meet the requirements of the Taiwanese Health Authorities for registration of ADACEL POLIO in Taiwan. Subjects will receive one dose of the study vaccine at 6 to 8 years of age. Blood samples will be taken for antibody titration. The expected total duration of follow-up for each subject will be 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TdcP-IPV vaccine | 0.5 mL, Intramuscular |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-04-01
- Completion
- 2009-07-01
- First posted
- 2008-11-25
- Last updated
- 2012-11-26
- Results posted
- 2012-11-26
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00797511. Inclusion in this directory is not an endorsement.